oral glp 1 tirzepatide FDA approves Eli Lilly's new once-daily drug for obesity Tirzepatide Oral | Starts at

Tirzepatide is the first antidiabetic drug that is a dual agonist of both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors

EAT-derived EVs can promote atrial fibrosis, impair intercellular conduction among cardiomyocytes, and induce local conduction blocks and conduction heterogeneity, thereby creating favorable conditions for arrhythmia reentry and persistence (105)

This past January, Shake Shack introduced its Good Fit Menu, which John Karangis, executive chef and VP of culinary innovation at Shake Shack, describes as approachable options that align with a range of lifestyles by focusing on protein, portion balance, and customization

Request a call 5-minute readPublished 05/15/2026Updated 11:10 AM EST, 06/08/2026 Sources Medicare GLP-1 Bridge opens in new window , Medicare.gov, last accessed April 24, 2026